摘要
目的采用Meta分析的方法综合评价家族序列相似性13A(FAM13A)基因rs7671167位点多态性与慢性阻塞性肺疾病(COPD)的关系。方法计算机检索PubMed、CNKI、万方、EMbase等数据库有关FAM13A基因rs7671167位点多态性与COPD发病风险的病例-对照研究,检索时间范围从建库至2016年6月20日。由两位研究者按照已制定的标准纳入文献并进行文献质量评价及资料提取。采用RevMan 5.3软件进行Meta分析。结果共纳入研究文献7篇,包括COPD组3 571例,对照组4 344例。Meta分析结果显示,在总体人群中,FAM13A基因rs7671167位点多态性与COPD易感性相关(CC+CT vs.TT,OR=0.76,95%CI=0.62~0.94,P<0.05);将人群按照种族不同进行分层分析,未发现FAM13A基因rs7671167位点多态性与亚洲人群COPD发病风险相关(CC+CT vs.TT,OR=0.82,95%CI=0.64~1.05,P>0.05);但在高加索人群中,FAM13A基因rs7671167位点多态性与COPD易感性相关(CC+CT vs.TT,OR=0.63,95%CI=0.43~0.93,P<0.05)。结论 FAM13A基因rs7671167位点多态性与高加索人群COPD发病风险具有相关性,可能降低高加索人群COPD发病风险;尚不能确定FAM13A基因rs7671167位点及等位基因基因型与亚洲人群COPD发病风险相关。
Objective To comprehensively evaluate the association of FAM13 A gene polymorphism with chronic obstructive pulmonary disease(COPD)applying a meta-analysis. Methods A computer search of case-control studies regarding correlation between FAM13 A gene polymorphism and COPD in PubMed,CNKI,WanFang and EMbase database was conducted.The retrieval time range was from the day of building database to June 20,2016.In accordance with established standards,the literature was included,evaluated and data extracted by two reviewers.A Meta-analysis was done adopting RevMan 5.3software.Results A total of seven studies involving 3 571 COPD cases and 4 344 healthy controls were included.The Meta-analysis demonstrated that COPD susceptibility was correlated with FAM13Ars7671167polymorphism(CC+CT vs.TT:OR=0.76,95%CI=0.62-0.94,P〈0.05).In the subgroup analysis by ethnicity,significant decreased risk of COPD was found in the Caucasian C allele carriers(CC+CT vs.TT:OR=0.63,95%CI=0.43-0.93,P〈0.05),but not in Asian(CC+CT vs.TT:OR=0.82,95%CI=0.64-1.05,P〉0.05). Conclusion FAM13 A gene rs7671167 polymorphism is correlated with susceptibility of COPD in Caucasian,which may decrease the onset risk of COPD in Caucasian,but the correlation of risk of COPD with FAM13 Agene rs7671167polymorphism in Asian is still not sure.
出处
《齐鲁医学杂志》
2017年第3期315-318,320,共5页
Medical Journal of Qilu
基金
四川省科技厅基金资助项目(2014JY0176)